Program Information
Novel Hardware and Software Platform for Intermediate Energy 4p Radiotherapy
K Woods1*, M Harrison2 , S Boucher2 , J McNevin2 , S Kutsaev2 , L Faillace2 , K Sheng1 , (1) UCLA School of Medicine, Los Angeles, CA, (2) RadiaBeam Technologies, Santa Monica, California
Presentations
TH-EF-BRB-7 (Thursday, August 4, 2016) 1:00 PM - 2:50 PM Room: Ballroom B
Purpose: To develop a robust and efficient platform for the optimization and robotic delivery of highly noncoplanar intensity modulated radiotherapy, which enables significant reduction of normal tissue toxicity and escalation of tumor dose.
Methods: An innovative high-output compact 3 MV linac was designed for mounting onto a commercial robotic system in order to access the entire 4π beam solution space without moving the patient couch. The use of intermediate energy X-rays for radiotherapy was evaluated in comparison to clinical plans delivered using 6 MV X-rays and a state-of-the-art delivery system. Monte Carlo simulations of a 3 MV percent depth dose curve were performed for intermediate energy dose calculation. The beam model was used to create a convolution/superposition-based dose calculation engine for 3MV X-rays. The 4π greedy column generation algorithm was used for optimized beam selection and fluence map optimization.
Results: A detailed design of the first 3 MV linac capable of producing a competitively high dose rate of >800 cGy/min at 100 cm was completed and verified through extensive simulation. The complete linac head including a multileaf collimator can access most of the 4π solution space including the posterior orientations without changing the couch height. When compared to 6 MV clinical plans, the proposed 3 MV 4π plans demonstrated significantly better dose compactness and normal tissue sparing in brain, prostate, and partial breast treatment plans.
Conclusion: We demonstrate the design of a highly versatile radiotherapy machine to natively deliver non-coplanar 4π radiotherapy without the need to move the patient during treatment. This novel platform is efficient and capable of providing dosimetry that is 30-50% more compact than existing therapy platforms. The new system is projected to be cost effective due to improved treatment time and automation.
Funding Support, Disclosures, and Conflict of Interest: NIH R43CA183390, NIH R01CA188300
Contact Email: